The Effect of Bevacizumab on Corneal Ne… | Clinical Trial

Key information

Conditions

Corneal Neovascularization Corneal Diseases Eye Diseases Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

About this study

To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization.

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Corneal Neovascularization
Stable lesion

Exclusion criteria

Diabetes
Autoimmune diseases

Treatment and study plan

Bevacizumab

Drug

subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months

Primary outcomes

The Effect of Bevacizumab on Corneal Neovascularization

Time frame: Compare the results

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography

Sponsors and collaborators

Lead sponsor

Instituto de Olhos de Goiania

Other

Registry information

Acronym: BQ-1-08-ARVO

Important dates

Study start: 2006
Primary completion: 2008
Study completion: 2008
First posted: Nov 25, 2008
Registry last updated: Dec 2, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed